Maze Therapeutics announced positive topline results from its Phase 2 HORIZON trial of MZE829, showing a significant reduction in proteinuria in patients with APOL1-mediated kidney disease (AMKD). The drug demonstrated a 35.6% mean reduction in urinary albumin-to-creatinine ratio at week 12, with no serious adverse events reported. Maze plans to advance MZE829 into a pivotal program and start two Phase 2 trials for MZE782 targeting phenylketonuria and chronic kidney disease in 2026. The company also strengthened its board with Neil Kumar, CEO of BridgeBio, and reported a strong cash position of $360 million, supporting operations into 2028.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, will announce its financial results for Q2 2026 on August 6, 2026. The company will host a conference call and webcast to discuss the results and recent bus...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
